Showing papers by "Delbert Robinson published in 2010"
TL;DR: This review suggests that many previous findings can be reinterpreted in this light, and makes several suggestions about test construction, study design, and statistical analyses that the field might use to overcome this potential confound.
110 citations
TL;DR: The relationship between -141C Ins/Del (rs1799732), a functional promoter region polymorphism in DRD2, and antipsychotic-induced weight gain in first episode schizophrenia patients enrolled in a randomized trial of risperidone versus olanzapine was examined.
Abstract: Many antipsychotic medications carry a substantial liability for weight gain, and one mechanism common to all antipsychotics is binding to the dopamine D2 receptor. We therefore examined the relationship between −141C Ins/Del (rs1799732), a functional promoter region polymorphism in DRD2, and antipsychotic-induced weight gain in 58 first episode schizophrenia patients enrolled in a randomized trial of risperidone (RIS) vs. olanzapine (OLZ). Carriers of the deletion allele (n=29) were compared to Ins/Ins homozygotes (non-carriers, n=29) in a mixed model encompassing 10 weight measurements over 16 weeks. Deletion allele carriers demonstrated significantly more weight gain after 6 weeks of treatment regardless of assigned medication. While deletion carriers were prescribed higher doses of OLZ (but not RIS), dose did not appear to account for the genotype effects on weight gain. Given previous evidence that deletion carriers demonstrate reduced symptom response to medication, additional study of appropriate treatment options for these patients appears warranted.
80 citations
Journal Article•
TL;DR: Patients with first-episode schizophrenia have an 81.9% chance of relapse within five years of initial episode, and only 13.7% of FE patients experience ≥2 years of sustained recovery, so a long-acting injectable medication may be necessary in cases of chronic non-adherence.
Abstract: Patients with first-episode (FE) schizophrenia have an 81.9% chance of relapse within five years of initial episode, and only 13.7% of FE patients experience ≥2 years of sustained recovery. Medication non-adherence is the greatest predictor of relapse. Approximately 40% of FE patients are non-adherent, and ~60% have intermittent periods of non-adherence. Antipsychotic switching/augmentation strategies may be required in order to stabilize patients and prepare them for a maintenance regimen. To achieve the desired 60% to 80% striatal dopamine blockade and avoid EPS/akathisia, careful consideration must be given to many practical intra-individual and inter-individual variations relating to drug absorption and metabolism. It is especially important to account for the receptor profiles of the pre- and post-switch antipsychotics. Quantitative assessments are very helpful in determining baseline severity and worsening/improvement. Second-generation antipsychotics have demonstrated better rates of adherence in schizophrenia compared to first-generation antipsychotics, although a long-acting injectable medication may be necessary in cases of chronic non-adherence.
2 citations